BIOVECTRA is pleased to be part of a Canadian solution with our NGEN partners CCRM, Precision Nanosytems (Cytiva), Northern RNA, and OmniaBio to establish a Canadian supply chain network to accelerate and standardize lentiviral vector development from clinical to commercial manufacturing. Together we are building a next-generation immunotherapy manufacturing platform that will be used for new […]
CHARLOTTETOWN, PRINCE EDWARD ISLAND, November 17th, 2023 – Today BIOVECTRA celebrates the completion of its $90 million plus biologics expansion at the company’s new state-of-the-art Biomanufacturing Centre with project partners the Government of Canada and Government of Prince Edward Island. “This expansion places BIOVECTRA at the forefront of supporting the next generation of treatments for today’s […]
CHARLOTTETOWN, Prince Edward Island and VANCOUVER, British Columbia, October 5, 2023 – BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service agreement under which BIOVECTRA will accept, on a non-exclusive basis, Acuitas’ best-in-class LNP technology platform for manufacturing mRNA-based therapeutics. “We are thrilled about this partnership with Acuitas […]
Charlottetown, P.E.I. (January 18, 2023) – BIOVECTRA is pleased to announce that Normand Blais was appointed as Senior Director, Development & Innovation, Biologics. Reporting to the Chief Science Officer, Mr. Blais will be responsible for the strategic direction shaping BIOVECTRA’s pDNA & mRNA vaccine process science program. Mr. Blais is accomplished in early-candidate vaccine […]
Charlottetown, P.E.I. (November 22, 2022) – BIOVECTRA was selected as one of Canada’s Top 100 Employers for a second consecutive year and is considered amongst the country’s leading workplaces. BIOVECTRA is a fast growing, forward-thinking contract development, and manufacturing organization (CDMO) solving complex challenges to improve patient care for some of the world’s top […]
Charlottetown, CANADA, October 31, 2022 – BIOVECTRA is ready to accept projects at its manufacturing facility in Windsor, Nova Scotia, Canada, for its new, single-use biologics fermentation suite. Containing 100 L and 1,000 L single-use fermenters, this state-of-the-art process train enhances BIOVECTRA’s microbial fermentation overall network of capacity and allows BIOVECTRA to support even […]
CHARLOTTETOWN, PEI – BIOVECTRA was recently named to Communitech’s True North list as one of Canada’s high performing tech companies that has a promising growth trajectory. Team True North is a roster of Canadian innovation companies shown by verified data to have the highest probability of reaching $1B in revenue. As global markets experience […]
Charlottetown, P.E.I. (April 14, 2022) – BIOVECTRA broke ground today, with help from provincial and federal officials, on a cutting-edge facility that will manufacture mRNA vaccines and therapeutics starting in 2023. BIOVECTRA’s mRNA Vaccine and Biomanufacturing Centre will add 36,000 square feet to its existing Charlottetown campus and, when operational, the cGMP facility will […]
Charlottetown, P.E.I. (November 18, 2021) – BIOVECTRA today announced plans for the development of a state-of-the-art facility specializing in the production and manufacturing of mRNA vaccines and therapeutics – one of the first of its kind in Canada. This exciting new capability will result from a joint private-public investment made by BIOVECTRA and the […]
Charlottetown, P.E.I. (November 12, 2021) – BIOVECTRA is proud to be selected as one of Canada’s Top 100 Employers for 2022 and considered amongst some of the country’s leading workplaces. As one of four Atlantic Canadian companies selected, BIOVECTRA is a fast growing, forward-thinking, global pharmaceutical contract development and manufacturing organization (CDMO) solving complex challenges […]
With over 50 years of experience, we are a forward-thinking,
North American CDMO specializing in clinical-to-commercial scale production of high-quality regulated APIs and Intermediates.